IDS Ltd

Investor Relations - Board Details

David Evans BCom., CA, MBA (aged 50)

David has considerable expertise within the diagnostic industry. As Financial Director, he was a key member of the team that floated Shield Diagnostics Group plc in 1993, and was the Chief Executive Officer responsible for the merger of Shield Diagnostics Group plc with Axis Biochemicals ASA of Norway in 1999 to create Axis-Shield plc. He is currently involved in a non-executive capacity with several other companies.

Roger Duggan PhD (aged 61), Managing Director

Roger joined RIA (UK), the forerunner of IDS, in 1981. Within IDS, he has held the positions of Development Scientist, Laboratory Manager, and Scientific Director, becoming Managing Director following the management buy-out in 1996. Roger also sits on the boards of PeriNatal Diagnostics Limited, PalindromX Limited, Pyrronostics Limited, Briefvision Limited,Phabia Limited and IDS Inc.

Paul Hailes FCCA (aged 47), Finance Director

Paul gained experience with Bowater plc and Courtaulds plc before joining IDS in February 1993. Paul is also a Director and/or Company Secretary in PeriNatal Diagnostics Limited, PalindromX Limited, Pyrronostics Limited, Briefvision Limited and Phabia Limited.

Anthony "Tony" Wilks (aged 49) Sales and Marketing Director

Living for more than twenty years in Germany and with eighteen years experience in European sales and marketing of diagnostic products, Tony brings a wealth of experience in international sales to IDS. Tony joined IDS in February 2005, from Nichols Institute Diagnostics GmbH, a wholly-owned subsidiary of Quest Diagnostics, the US parent where he acted as Managing Director of European Operations. Tony had been with Nichols Institute since 1997. In 1990 Tony started Tosoh Medics GmbH in Germany and successfully established Tosoh as a major diagnostic company in immunoassay automation. Prior to this Tony was Product Manager for Oxford Medical Systems GmbH, responsible for cardiovascular system, marketing and distribution sales.

Martha Louise Garrity PHD (aged 49) Technical Director

Martha joined IDS in February 2007, after eleven years in Research and Development at Nichols Institute Diagnostics as a Senior Scientist, Manager and Director. She was a key member of the team created to convert the established immunoassays of NID into fully-automated formats for the Nichols Advantage. At NID she contributed to the development and launch of automated specialty assays in the areas of of bone, growth, thyroid, and hypertension, and gained expertise in chemiluminescent labels and magnetic particles, which are the specific technologies to be employed by IDS in the automation of its unique range of bone and skeletal biomarkers.

Christopher "Ian" Cookson, (aged 56), Operations Director

Ian brings more than twenty years of experience gained in senior appointments within the in vitro diagnostics (IVD) industry both in the UK and overseas and a skill set of particular relevance to the forward strategic plans of IDS. Ian joined IDS from Axis-Shield plc, where he was Managing Director of their Dundee-based Laboratory Division. As well as his general management skills he has been heavily involved in facilities design, quality and regulatory requirements, manufacturing scale-up and manufacturing transfer during recent years. His extensive experience of automated immunoassay systems will be particularly relevant to his position as Operations Director of IDS as the Company brings its own automated system to the market.

Alain Rousseau (aged 59), Engineering Director

Alain gained his experience in both the high-tech sensors and automotive industries before turning his skills to the in vitro diagnostics market. He has filed for over 30 patents in these areas over the course of his career. As Head of Instrumentation for the well-known Diagnostica Stago, he created and developed the production of the entire instrumentation product line. Alain joined Biocode Hycel in mid 2003 as CEO, to develop a new innovative and multidisciplinary platform which is now the 3X3 automated system. As part of the Biocode acquisition, Alain joins the IDS Board to drive automation manufacture and system design going forward.

Patrik Dahlén (aged 47), Non-Executive Director

Dr. Dahlén has over twenty years experience in the diagnostic and life science industry. He became Chief Executive Officer of Chempaq A/S, the Denmark-based Point of Care diagnostics company in November 2009 having been CEO of Dako A/S since 2005. Previously he was CEO of BioImage, Senior Vice President of Perkin-Elmer Inc and President of Perkin-Elmer Life Sciences. He is Chairman of OLink Biosciences and Proxeon.

Edward "Eddie" Blair PhD (aged 49), Non-Executive Director

Following a research career in virology at the MRC National Institute for Medical Research (Mill Hill, London) and the University of California (Irvine CA, US), Eddie spent fifteen years in the pharmaceutical industry and held the positions of Programme Leader in Virology then later Clinical Therapeutic Adviser to the Predictive Medicine Group at GlaxoWellcome, before becoming a director of clinical diagnostics at GlaxoSmithKline plc. He is currently a director of Integrated Medicines Limited.

Dr. Burkhard Wittek (Age 58), Non-Executive Director

Dr. Wittek, aged 57, holds an MBA from Harvard Business School. After working for Dresdner Bank AG he spent thirteen years with The Boston Consulting Group where he was a senior partner with worldwide responsibility for the consumer goods / retail and healthcare sectors. In 1990 he founded FORUM Family Office which makes long-term investments in German Private Equity and European Small and Midcap situations.